Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
Filing Date
Mar 27, 2019
Document Date
Mar 27, 2019
Form Description
Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3
Filing Group
Registration Statements
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp